Ricerc@Sapienza

Background: Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. Methods: We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in patients with treatment-naïve NSCLC and a PD-L1 expression of ≥ 50%. Results: One thousand and twenty-six consecutive patients were included.

Sinonasal undifferentiated carcinoma (SNUC) is a rare malignancy arising from the nasal cavity with neuroendocrine differentiation and aggressive behavior. When first diagnosed, SNUC is often locally advanced with nodal and distant metastases. The present study indicates a rare case of sole metastases to the liver from maxillary sinus undifferentiated carcinoma. Diagnosis was confirmed by total body computed tomography and immunohistochemical analysis on tissues from both maxillary and liver neoplastic tissues. SNUC is an aggressive malignancy characterized by a poor prognosis.

Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor. The aim of this study is to present an up-to-date review of treatment options for patients with liver metastases from PNETs.